About Nicotinell
Nicotinell is one of the world's leading nicotine replacement therapy (NRT) brands, developed by Ciba-Geigy (now Novartis) and launched in 1990 as the first nicotine patch available worldwide. The brand dominated the NRT category during the late 1990s and remains the world's second-leading NRT brand by sales, ranking among the top 15 over-the-counter products in Europe. The Nicotinell range includes nicotine patches, lozenges, and gum, offering multiple delivery methods to help smokers quit. The patches were developed based on research from UCLA, using transdermal technology to release nicotine gradually through the skin over 24 hours. Lozenges and gum provide faster nicotine delivery for managing sudden cravings throughout the day. Nicotinell's ownership has evolved over the years. The brand was part of Haleon, the consumer health company formed from Pfizer and GSK's over-the-counter businesses and spun off from GSK in 2022. In 2024, Haleon sold its non-US NRT business, powered primarily by Nicotinell, to Dr. Reddy's for approximately £500 million ($633 million). British shoppers can find Nicotinell patches, lozenges, and gum at UK supermarkets and pharmacies. The products are available in various strengths to support different stages of the quitting journey, from full-strength for heavy smokers to lower doses for gradual reduction.















